242 related articles for article (PubMed ID: 16682722)
21. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
Peroutka JA; Mutnick AH
Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
Hirsch BR; Lyman GH
Pharmacoeconomics; 2012 Jun; 30(6):497-511. PubMed ID: 22540394
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic growth factors--not whether, but when and where.
Hoelzer D
N Engl J Med; 1997 Jun; 336(25):1822-4. PubMed ID: 9187075
[No Abstract] [Full Text] [Related]
25. Study inclusion criteria and presentation of results in a meta-analysis of granulocyte colony-stimulating factor for prevention of febrile neutropenia.
Lathia N; Isogai PK; Cheung MC; Mittmann N
J Clin Oncol; 2010 Dec; 28(36):e762-3; author reply e764. PubMed ID: 21079143
[No Abstract] [Full Text] [Related]
26. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
Crea F; Giovannetti E; Zinzani PL; Danesi R
Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
[TBL] [Abstract][Full Text] [Related]
27. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
28. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
29. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
Wingard JR; Elmongy M
Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
[TBL] [Abstract][Full Text] [Related]
30. [A general description of the clinical guideline for the management of febrile neutropenia].
Takamatsu Y
Gan To Kagaku Ryoho; 2013 Jun; 40(6):697-702. PubMed ID: 23863646
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
[No Abstract] [Full Text] [Related]
33. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
34. Use of myeloid growth factors for patients with febrile neutropenia: plus ca change, plus c'est la même chose.
Schiffer CA
Pediatr Blood Cancer; 2005 Sep; 45(3):242-3. PubMed ID: 15983983
[No Abstract] [Full Text] [Related]
35. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
Jørgensen HG; Copland M; Holyoake TL
Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
[No Abstract] [Full Text] [Related]
36. The costs of treating febrile neutropenia in six U.K. Hospitals.
Leese B
Eur J Cancer; 1993; 29A Suppl 7():S15-8. PubMed ID: 7508725
[TBL] [Abstract][Full Text] [Related]
37. Prechemotherapy assessment of neutropenic risk.
Doyle AM
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):32-9; discussion 39-40. PubMed ID: 18153977
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
[TBL] [Abstract][Full Text] [Related]
39. [Myelosuppression due to antineoplastic agents].
Shigeoka Y; Shimizu E
Nihon Rinsho; 2007 Oct; 65 Suppl 8():287-93. PubMed ID: 18074550
[No Abstract] [Full Text] [Related]
40. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
